[1]
A. Marcellusi, C. Bini, M. A. Rotundo, R. Cultrera, and F. S. Mennini, “Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy”, Grhta, vol. 7, no. 1, pp. 92–100, Nov. 2020.